Emmaus Life Sciences, Inc. (EMMA-OTCQX)

Emmaus Life Sciences, Inc. (“Emmaus” or “the Company”) is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies, primarily for rare and orphan diseases, with an initial focus on Sickle Cell Disease (SCD). Emmaus’ lead commercial product is Endari® (L-glutamine oral powder), an oral treatment indicated to reduce acute complications of SCD in adult and pediatric patients. Emmaus’ domestic operations are in addition to the Company’s international business expansion, where Endari® received marketing approval in three Middle Eastern and North African countries during 2022 (United Arab Emirates, Qatar, and Kuwait). Emmaus is aggressively seeking additional marketing approval in geographic regions that account for a significant share of the world’s SCD cases, with applications submitted in Saudi Arabia, Bahrain, and Oman, as well as expected additional approvals in this region, Europe, and Asia. Following its market introduction, Endari® achieved year-over-year revenue growth until it experienced negative impacts as a result of COVID-19. The Company has since regained its growth position in the second half of 2022, driven by the effective use of its in-house sales force and its newly launched direct-to-consumer programs, including an innovative full-service telehealth solution that provides online access to Endari®. Emmaus is also involved in assessing L-glutamine to treat diverticulosis, currently in a pilot trial, as well as pre-clinical programs for oncology and regenerative medicine with other compounds. The Company believes its Endari® commercial activities and pipeline of new products provide a sustainable business model, which could result in multiple future revenue sources.

* The Corporate Snapshot was last updated on January 24, 2023.